FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2673884370> ?p ?o ?g. }

• W2673884370 abstract "Since its early development, the vascular endothelial growth factors (VEGFRs) inhibitor pazopanib showed both activity and tolerability in patients with metastatic RCC (mRCC) (Hurwitz et al., 2009), results which were subsequently confirmed in the following studies. A phase II study was at first designed as a randomized discontinuation study, but lately revised to an open-label study based on week 12 response rate (RR) of 38% in the first 60 patients. Thus, the primary end-point was changed from progressive disease rate at 16 weeks post-randomization to RR (Hutson et al., 2010). Overall RR was 35%, median duration of response was 68 weeks, and median progression-free survival (PFS) was 52 weeks (Hutson et al., 2010).Pazopanib was registered based on a global randomized, placebo-controlled, phase III trial. Of the 435 patients enrolled, 233 (54%) were treatment-naive, while 202 (46%) were pre-treated with cytokines. Pazopanib significantly prolonged PFS in overall study population [median PFS: 9.2 vs. 4.2 months, hazard ratio (HR): 0.46, 95% CI: 0.34–0.62, p < 0.0001], in the cytokine-pretreated subpopulation, as well as in the treatment-naive subpopulation (median PFS: 11.1 vs. 2.8 months, HR: 0.40, 95% CI: 0.27–0.60, p < 0.0001), compared to placebo (Sternberg et al., 2010). Furthermore, the objective response rate (ORR) was 30% with pazopanib with a median duration of response longer than 1 year. None clinically important difference in quality of life for pazopanib vs. placebo was observed in the safety analysis (Sternberg et al., 2010).More recently, the phase III COMPARZ study directly compared pazopanib with sunitinib in a non-inferiority study (Escudier et al., 2014). Pazopanib was non-inferior to sunitinib in terms of PFS (HR: 1.05, 95% CI: 0.90–1.22—predefined upper bound of the 95% CI < 1.25), and similar in OS (HR: 0.91, 95% CI: 0.76–1.08; Motzer et al., 2013); ORR was higher for pazopanib, as compared to sunitinib (31 vs. 25%, p = 0.03; Motzer et al., 2013). In terms of safety, pazopanib-treated patients experienced less fatigue, fewer side effects, including soreness of hand/foot and mouth/throat, and were more satisfied with treatment than those who received sunitinib (Motzer et al., 2013; Table ​Table1).1). Less fatigue and better overall quality of life were the most common reasons that justified the preference of pazopanib vs. sunitinib (70 vs. 22%, p < 0.01) in the PISCES study, a cross-over, double blind trial which specifically assessed the innovative endpoint of patients' preference (Escudier et al., 2014).Table 1Comparison of baseline characteristics, clinical outcomes and adverse events in pivotal studies." @default.
• W2673884370 created "2017-06-30" @default.
• W2673884370 creator A5018910230 @default.
• W2673884370 creator A5038289551 @default.
• W2673884370 creator A5049048398 @default.
• W2673884370 creator A5050178891 @default.
• W2673884370 date "2017-06-21" @default.
• W2673884370 modified "2023-10-17" @default.
• W2673884370 title "Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient" @default.
• W2673884370 cites W1946423307 @default.
• W2673884370 cites W1971358860 @default.
• W2673884370 cites W2021770899 @default.
• W2673884370 cites W2022249378 @default.
• W2673884370 cites W2026912241 @default.
• W2673884370 cites W2044365534 @default.
• W2673884370 cites W2049909846 @default.
• W2673884370 cites W2055557358 @default.
• W2673884370 cites W2093356247 @default.
• W2673884370 cites W2095771928 @default.
• W2673884370 cites W2102729420 @default.
• W2673884370 cites W2115966993 @default.
• W2673884370 cites W2116949558 @default.
• W2673884370 cites W2130953539 @default.
• W2673884370 cites W2131444088 @default.
• W2673884370 cites W2131859250 @default.
• W2673884370 cites W2134580389 @default.
• W2673884370 cites W2143782771 @default.
• W2673884370 cites W2160888189 @default.
• W2673884370 cites W2162424705 @default.
• W2673884370 cites W2167678372 @default.
• W2673884370 cites W2177013746 @default.
• W2673884370 cites W2177103886 @default.
• W2673884370 cites W2293115567 @default.
• W2673884370 cites W2485311469 @default.
• W2673884370 cites W2486639626 @default.
• W2673884370 cites W2507098989 @default.
• W2673884370 cites W2590066672 @default.
• W2673884370 cites W2600306685 @default.
• W2673884370 doi "https://doi.org/10.3389/fphar.2017.00329" @default.
• W2673884370 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5478711" @default.
• W2673884370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28680399" @default.
• W2673884370 hasPublicationYear "2017" @default.
• W2673884370 type Work @default.
• W2673884370 sameAs 2673884370 @default.
• W2673884370 citedByCount "4" @default.
• W2673884370 countsByYear W26738843702017 @default.
• W2673884370 countsByYear W26738843702019 @default.
• W2673884370 countsByYear W26738843702020 @default.
• W2673884370 countsByYear W26738843702023 @default.
• W2673884370 crossrefType "journal-article" @default.
• W2673884370 hasAuthorship W2673884370A5018910230 @default.
• W2673884370 hasAuthorship W2673884370A5038289551 @default.
• W2673884370 hasAuthorship W2673884370A5049048398 @default.
• W2673884370 hasAuthorship W2673884370A5050178891 @default.
• W2673884370 hasBestOaLocation W26738843701 @default.
• W2673884370 hasConcept C126322002 @default.
• W2673884370 hasConcept C142724271 @default.
• W2673884370 hasConcept C143998085 @default.
• W2673884370 hasConcept C1491633281 @default.
• W2673884370 hasConcept C2777472916 @default.
• W2673884370 hasConcept C2778439243 @default.
• W2673884370 hasConcept C2779490328 @default.
• W2673884370 hasConcept C2781278892 @default.
• W2673884370 hasConcept C502942594 @default.
• W2673884370 hasConcept C54355233 @default.
• W2673884370 hasConcept C71924100 @default.
• W2673884370 hasConcept C86803240 @default.
• W2673884370 hasConceptScore W2673884370C126322002 @default.
• W2673884370 hasConceptScore W2673884370C142724271 @default.
• W2673884370 hasConceptScore W2673884370C143998085 @default.
• W2673884370 hasConceptScore W2673884370C1491633281 @default.
• W2673884370 hasConceptScore W2673884370C2777472916 @default.
• W2673884370 hasConceptScore W2673884370C2778439243 @default.
• W2673884370 hasConceptScore W2673884370C2779490328 @default.
• W2673884370 hasConceptScore W2673884370C2781278892 @default.
• W2673884370 hasConceptScore W2673884370C502942594 @default.
• W2673884370 hasConceptScore W2673884370C54355233 @default.
• W2673884370 hasConceptScore W2673884370C71924100 @default.
• W2673884370 hasConceptScore W2673884370C86803240 @default.
• W2673884370 hasLocation W26738843701 @default.
• W2673884370 hasLocation W26738843702 @default.
• W2673884370 hasLocation W26738843703 @default.
• W2673884370 hasLocation W26738843704 @default.
• W2673884370 hasLocation W26738843705 @default.
• W2673884370 hasOpenAccess W2673884370 @default.
• W2673884370 hasPrimaryLocation W26738843701 @default.
• W2673884370 hasRelatedWork W2056454490 @default.
• W2673884370 hasRelatedWork W2154171266 @default.
• W2673884370 hasRelatedWork W2397084084 @default.
• W2673884370 hasRelatedWork W2469034648 @default.
• W2673884370 hasRelatedWork W2590554596 @default.
• W2673884370 hasRelatedWork W2767323531 @default.
• W2673884370 hasRelatedWork W2767622789 @default.
• W2673884370 hasRelatedWork W2810031013 @default.
• W2673884370 hasRelatedWork W2896264118 @default.
• W2673884370 hasRelatedWork W3163179811 @default.
• W2673884370 hasVolume "8" @default.
• W2673884370 isParatext "false" @default.
• W2673884370 isRetracted "false" @default.
• W2673884370 magId "2673884370" @default.

• next